A third-party clinical research organization (CRO) prepared and administered the PreCardix® bioactive marine peptide clinical trial per clinical research standards governed by ethics review committees in Europe and North America. The study has been peer-reviewed and published by one of the world’s leading hypertension & cardiology journals: the International Journal of Hypertension. Please find the study here. PreCardix® is the result of over a decade of research conducted in partnership with the University of Tromso Norway, the R&D Institute Norfima, and Marealis Health Inc. You can learn more about the clinical studies here.